Please amend specification passage at page 6, lines ~~3-21~~ 1-19 as follows: SB 2-1-08

Suitable values of R^1, R^2, R^3, R^4, R^5 and p are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

R^1 is fluoro, chloro, cyano, methyl, ethyl, methoxy or ethoxy.

p is 0.

p is 1.

p is 2.

R^2 is R^6-NH-~~R^6-NH_2~~- wherein R^6 is C_{1-4}alkyl, C_{2-4}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl or (heterocyclic group)C_{1-3}alkyl; and wherein R^6 may be optionally substituted on carbon by one methoxy, ethoxy or trifluoromethyl.

R^2 is R^6-NH-~~R^6-NH_2~~- wherein R^6 is C_{1-4}alkyl, C_{2-4}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl or (heterocyclic group)C_{1-3}alkyl; and wherein R^6 may be optionally substituted on carbon by one methyl, methoxy, ethoxy or trifluoromethyl.

R^2 is R^6-NH-~~R^6-NH_2~~- wherein R^6 is methyl, ethyl, propyl, *t*-butyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, tetrahydrofur-2-ylmethyl or pyrid-2-ylmethyl; and wherein R^6 may be optionally substituted on carbon by one methoxy, ethoxy or trifluoromethyl.

R^2 is R^6-NH-~~R^6-NH_2~~- wherein R^6 is methyl, ethyl, propyl, *t*-butyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, tetrahydrofur-2-ylmethyl or pyrid-2-ylmethyl; and wherein R^6 may be optionally substituted on carbon by one methyl, methoxy, ethoxy or trifluoromethyl.

Please amend specification passage at page 7, lines ~~15-30~~ 13-28 as follows: SB 2-1-08

Therefore in another aspect of the invention, there is provided a compound of formula **(I)** (as depicted above) wherein:

p is 0;

R^2 is R^6-NH-~~R^6-NH_2~~- wherein R^6 is C_{1-4}alkyl, C_{2-4}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl or (heterocyclic group)C_{1-3}alkyl; and wherein R^6 may be optionally substituted on carbon by one methoxy, ethoxy or trifluoromethyl;

R^3 is hydrogen;

R^4 is C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-4}alkyl, heterocyclyl or 1-methoxyprop-2-yl;

R^5 is C_{1-6}alkyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Therefore in another aspect of the invention, there is provided a compound of formula **(I)** (as depicted above) wherein:

p is 0;

R^2 is $\underline{R^6\text{-NH-}}$ ~~$R^6\text{-NH}_2$~~- wherein R^6 is C_{1-4}alkyl, C_{2-4}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl or (heterocyclic group)C_{1-3}alkyl; and wherein R^6 may be optionally substituted on carbon by one methoxy, ethoxy or trifluoromethyl;

Please amend specification passage at page 10, lines 4-11 as follows: SB 2-1-08

Process c) for compounds of formula **(I)** where R^2 is amino or a group $\underline{R^6\text{-NH-}}$ ~~$R^6\text{-NH}_2$~~-; reacting a pyrimidine of formula **(VI)**:



(VI)

wherein X is a displaceable group; with an amine of formula **(VII)**:

$R^a\text{-NH}_2$

(VII)

wherein R^a is hydrogen or R^6;